Testosterone Cypionate Mechanism of Action: Full Pathway From Injection to Androgen Receptor

Step 1: The Depot Effect and Ester Hydrolysis

Testosterone cypionate does not enter the bloodstream as active hormone at the moment of injection. The cyclopentylpropionate ester attached at the 17-beta hydroxyl group makes the molecule highly lipophilic, causing it to partition into the oily depot that forms within muscle tissue [1]. This is the rate-limiting step that gives cypionate its prolonged duration of action.

Non-specific tissue esterases gradually cleave the ester bond, releasing free (unesterified) testosterone into surrounding capillaries. The hydrolysis rate depends on ester chain length. Testosterone propionate (3-carbon ester) clears in roughly 2 days. Testosterone enanthate (7-carbon) and cypionate (8-carbon) share similar kinetics, with cypionate showing a terminal half-life of approximately 8 days in pharmacokinetic studies [2]. Peak serum concentrations typically arrive 24 to 48 hours after a standard intramuscular dose of 200 mg [1].

Once free testosterone reaches systemic circulation, it binds to sex hormone-binding globulin (SHBG) with high affinity (roughly 44% of circulating testosterone) and to albumin with lower affinity (roughly 54%). Only about 2 to 3% circulates as unbound, bioavailable hormone [3]. The SHBG-bound fraction is generally considered biologically inactive at the tissue level, while albumin-bound testosterone dissociates readily in capillary beds and contributes to tissue uptake.

The 2018 Endocrine Society guideline recommends monitoring trough testosterone levels (drawn immediately before the next injection) to confirm that the depot is sustaining concentrations within the adult male reference range of 300 to 1 to 000 ng/dL [3].

Step 2: Androgen Receptor Binding and Genomic Signaling

Free testosterone crosses cell membranes by passive diffusion and binds the androgen receptor (AR), a ligand-activated transcription factor encoded by the AR gene on chromosome Xq11-12. The AR belongs to the nuclear receptor superfamily (designated NR3C4) [4]. This is the central molecular event through which testosterone cypionate exerts most of its physiological effects.

In the unliganded state, the AR sits in the cytoplasm complexed with heat-shock proteins (HSP90, HSP70, and co-chaperones). Testosterone binding triggers a conformational change that releases these chaperones, exposes a nuclear localization signal, and allows the receptor to dimerize [4]. The AR homodimer then translocates to the nucleus, where it binds androgen response elements (AREs) in gene promoter regions.

Recruitment of coactivators (SRC-1, SRC-3, p300/CBP) and components of the basal transcription machinery drives expression of androgen-responsive genes. Target genes vary by tissue. In skeletal muscle, AR activation upregulates IGF-1, myosin heavy chain isoforms, and satellite cell proliferation genes [5]. In bone, AR signaling stimulates osteoblast differentiation markers including RUNX2 and osteocalcin [6].

The genomic pathway operates on a timescale of hours to days. Changes in gene transcription become measurable within 6 to 12 hours of receptor binding, but clinical effects on muscle mass, bone density, and erythropoiesis accumulate over weeks to months [3].

Step 3: Non-Genomic (Rapid) Signaling

Not every testosterone effect waits for gene transcription. A parallel non-genomic pathway operates within seconds to minutes. Membrane-associated AR or G-protein-coupled receptors (including GPRC6A and ZIP9) activate intracellular second-messenger cascades involving MAPK/ERK, PI3K/Akt, and intracellular calcium flux [7].

These rapid effects matter clinically. Testosterone-induced vasodilation in coronary arteries occurs within minutes and appears mediated by calcium-channel inhibition independent of nuclear AR [7]. Rapid signaling also modulates neuronal excitability and may contribute to the acute mood and energy changes some patients describe shortly after injection, well before genomic pathways have time to alter protein synthesis.

The relative contribution of non-genomic vs. genomic signaling remains an active research area. Most long-term clinical outcomes (body composition changes, bone accrual, erythropoiesis) depend on the slower genomic arm, but cardiovascular and neurological effects likely involve both pathways simultaneously [7].

Step 4: 5-Alpha Reduction to DHT

Testosterone is not the final active androgen in every tissue. The enzyme 5-alpha reductase (types I, II, and III) converts testosterone to dihydrotestosterone (DHT), which binds the same AR but with approximately 2 to 3 times greater affinity and 5 times slower dissociation [8]. DHT is the primary androgen driving prostate growth, sebaceous gland activity, and androgen-dependent hair follicle miniaturization.

Type II 5-alpha reductase (SRD5A2) predominates in the prostate, seminal vesicles, and hair follicles. Type I (SRD5A1) is more broadly expressed in liver and skin [8]. When exogenous testosterone cypionate raises systemic testosterone, more substrate is available for 5-alpha reduction. Serum DHT typically rises in parallel, and the DHT-to-testosterone ratio can shift depending on individual enzyme expression levels.

This conversion explains why some patients on testosterone replacement therapy (TRT) experience acne, oily skin, or accelerated androgenetic alopecia even when total testosterone is within the reference range [3]. The Endocrine Society guideline notes that monitoring DHT is not required routinely, but may be warranted if androgenic side effects are disproportionate to the testosterone level [3].

Step 5: Aromatization to Estradiol

The enzyme aromatase (CYP19A1), concentrated in adipose tissue, brain, bone, and the testes, irreversibly converts testosterone to 17-beta estradiol [9]. This is not a side reaction. Estradiol is essential for several outcomes historically attributed to testosterone itself.

Bone health provides the clearest example. Estradiol, not testosterone, is the dominant hormonal regulator of epiphyseal closure and adult bone mineral density in men. A landmark case report of a man with complete estrogen resistance (homozygous ER-alpha mutation) showed unfused epiphyses and severe osteoporosis despite normal testosterone, demonstrating that estrogen signaling is required for male skeletal maturation [10]. In the T-Trials bone substudy, testosterone treatment (including cypionate formulations) increased volumetric bone mineral density and estimated bone strength in men aged 65 and older with low testosterone (N=211), effects mediated in part through the aromatization pathway [11].

Estradiol also mediates testosterone's negative feedback on hypothalamic GnRH secretion (discussed below) and contributes to lipid metabolism and neuroprotection [9]. Serum estradiol levels in men on TRT typically range from 20 to 50 pg/mL. Excessive aromatization (often in men with higher adiposity) can push estradiol above this range, potentially contributing to gynecomastia and fluid retention [3].

Step 6: Hypothalamic-Pituitary-Gonadal Axis Feedback

Exogenous testosterone cypionate does not simply add to what the body already produces. It suppresses the entire hypothalamic-pituitary-gonadal (HPG) axis through negative feedback. This point is clinically important and frequently misunderstood.

Testosterone and its metabolite estradiol act on the hypothalamus to reduce pulsatile gonadotropin-releasing hormone (GnRH) secretion. With less GnRH reaching the anterior pituitary, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output drops. LH is the primary driver of Leydig cell testosterone synthesis, so endogenous production effectively shuts down [12]. FSH suppression simultaneously reduces spermatogenesis, which is why testosterone is under investigation as a male contraceptive approach.

In the 2018 Endocrine Society guideline, Dr. Shalender Bhasin and colleagues wrote: "Clinicians should inform patients that testosterone therapy suppresses spermatogenesis and that recovery of spermatogenesis after discontinuation is variable and may be prolonged" [3]. LH typically falls below the lower limit of detection within 2 to 4 weeks of starting standard-dose cypionate. Testicular volume decreases over months of continuous therapy due to reduced intratesticular testosterone and loss of seminiferous tubule stimulation.

This axis suppression is reversible in most men after discontinuation, but the timeline varies. A study of 66 men recovering from testosterone-induced azoospermia found median time to recovery of spermatogenesis was 3.4 months (range: 1 to 24 months) [13]. Younger men and those with shorter treatment durations recovered faster.

Tissue-Specific Effects: Muscle, Bone, Brain, and Blood

The mechanisms above converge differently in each organ system. Separating these tissue-level effects clarifies what cypionate actually does after the receptor biochemistry plays out.

Skeletal Muscle

Testosterone drives muscle protein synthesis through AR-mediated upregulation of IGF-1 and satellite cell activation [5]. In the T-Trials (N=790 in the physical function substudy), men aged 65 and older receiving testosterone gel for 12 months showed improved 6-minute walking distance compared with placebo, with a mean increase of 6.5 meters beyond placebo change [14]. The Bhasin dose-response studies demonstrated that muscle mass gains are dose-dependent: supraphysiologic doses of testosterone enanthate (600 mg/week) produced a 6.1 kg increase in fat-free mass over 20 weeks in healthy young men, even without exercise [5].

Erythropoiesis

Testosterone stimulates erythropoietin (EPO) production in the kidney and directly promotes erythroid progenitor proliferation in bone marrow [15]. In the T-Trials anemia substudy, testosterone treatment corrected unexplained anemia in 58.3% of treated men vs. 22.2% on placebo (N=126) [15]. Hemoglobin increases of 1.0 g/dL or more occurred in the majority of responders. This erythropoietic effect also explains why polycythemia (hematocrit above 54%) is the most common laboratory adverse event during TRT, requiring periodic CBC monitoring [3].

Bone

As described above, testosterone acts on bone through both direct AR signaling in osteoblasts and indirect estrogen-mediated pathways [6]. The T-Trials bone substudy reported increases in volumetric trabecular BMD of the lumbar spine by 7.5% over 12 months of testosterone treatment [11]. The American Association of Clinical Endocrinologists (AACE) recognizes testosterone replacement as a treatment option for osteoporosis in hypogonadal men [16].

Brain and Mood

The brain expresses both AR and estrogen receptors (ER-alpha, ER-beta). Testosterone and its metabolites influence mood, cognition, libido, and spatial memory through region-specific receptor activation in the amygdala, hippocampus, and prefrontal cortex [17]. In the T-Trials vitality substudy, men receiving testosterone reported modest but statistically significant improvements in sexual desire and erectile function compared with placebo, with a between-group difference in the PDQ-SF score of 0.58 (95% CI 0.15 to 1.01) [14].

Pharmacokinetic Considerations That Shape Clinical Response

The mechanism of action cannot be understood independently of pharmacokinetics. How much testosterone reaches the AR, and when, determines clinical response.

Standard intramuscular dosing of 100 to 200 mg every 7 to 14 days produces a characteristic "sawtooth" pattern: supraphysiologic peaks at 24 to 48 hours post-injection, followed by a gradual decline to near-trough levels by day 7 or 14 [2]. More frequent dosing (e.g., 50 to 80 mg twice weekly or even 20 to 30 mg every other day subcutaneously) flattens these peaks and troughs, potentially reducing peak-related side effects like mood fluctuation and erythrocytosis [3].

The Endocrine Society guideline states: "We suggest that clinicians aim for a steady-state testosterone level in the mid-normal range and avoid supraphysiologic peaks" [3]. Subcutaneous injection of testosterone cypionate, though off-label, has gained clinical acceptance after pharmacokinetic data confirmed comparable bioavailability with less injection-site pain [18].

Hepatic first-pass metabolism does not apply to injectable testosterone cypionate. The ester is cleaved peripherally, and free testosterone enters the systemic circulation directly from the depot. Testosterone is then metabolized in the liver primarily by CYP3A4 and conjugated for renal and biliary excretion [1]. Less than 6% of administered testosterone is excreted unchanged in urine.

Patients on concurrent CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) may experience modestly elevated testosterone levels due to slowed hepatic clearance, though dose adjustments are rarely needed in clinical practice [1].

Why the Cypionate Ester Specifically

Testosterone cypionate and testosterone enanthate are the two most commonly prescribed injectable esters in the United States. Their pharmacokinetic profiles are nearly identical, with cypionate showing a marginally longer half-life (8 days vs. approximately 7 days for enanthate) due to one additional carbon in the ester chain [2]. The FDA-approved labeling for testosterone cypionate (marketed historically as Depo-Testosterone) lists intramuscular injection every 1 to 4 weeks as the recommended schedule, though most contemporary protocols use weekly or biweekly intervals [1].

The cypionate ester was first synthesized in the 1950s and received FDA approval in 1979 for male hypogonadism [1]. Its widespread use in the U.S. is partly historical. Enanthate dominates in Europe and many other markets. From a mechanistic standpoint, once esterases cleave either ester, the resulting free testosterone molecule is identical. The ester choice affects only release kinetics, not receptor pharmacology.